RxDoctor Payments Data

Eric Smith, MD

Family Medicine · Grand Ledge, MINPI 1689748725

Payments from drug & device makers

$15,164in general payments, 2019–2025

Across 1,216 payments — averaging $12.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Pfizer$843
  • GSK$631
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$14,92698%
  • Education$2382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,164 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$95,599
Medicare patients
296
Services billed
1,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide260$386,649
EliquisApixaban164$193,268
OzempicSemaglutide120$186,128
JardianceEmpagliflozin92$115,170
FarxigaDapagliflozin Propanediol89$113,578
TrulicityDulaglutide47$106,636
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$65,178
XareltoRivaroxaban59$62,130
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$41,274
ProliaDenosumab23$39,014
MyrbetriqMirabegron28$32,103
Breo ElliptaFluticasone/Vilanterol27$19,840
Atorvastatin Calcium998$19,493
Repatha SureclickEvolocumab16$18,796
JanuviaSitagliptin Phosphate12$18,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,031$493,284307 claims
PfizerEliquis$843$193,268164 claims
Novo NordiskOzempic$3,123$186,128120 claims
Boehringer IngelheimJardiance, Stiolto Respimat$556$132,760107 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$631$126,293126 claims
AstraZenecaFarxiga$423$113,57889 claims
Johnson & JohnsonXarelto$450$62,13059 claims
AmgenProlia$1,491$39,01423 claims
Astellas Pharma US IncMyrbetriq$163$32,10328 claims
MerckJanuvia$372$18,76612 claims
Arbor Pharmaceuticals, Inc.Edarbi$15$2,94512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Ledge

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →